Partners Capital Investment Group LLP cut its holdings in shares of Kronos Bio, Inc. (NASDAQ:KRON - Free Report) by 67.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 527,500 shares of the company's stock after selling 1,084,012 shares during the quarter. Partners Capital Investment Group LLP owned approximately 0.87% of Kronos Bio worth $501,000 at the end of the most recent quarter.
Separately, Deltec Asset Management LLC purchased a new stake in Kronos Bio during the 4th quarter worth approximately $190,000. Institutional investors and hedge funds own 64.09% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on KRON shares. Piper Sandler downgraded Kronos Bio from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $6.00 to $1.00 in a report on Thursday, November 14th. TD Cowen downgraded Kronos Bio from a "buy" rating to a "hold" rating in a report on Thursday, November 14th.
View Our Latest Stock Report on KRON
Kronos Bio Stock Performance
Shares of NASDAQ KRON remained flat at $1.02 during trading on Thursday. The stock had a trading volume of 408,353 shares, compared to its average volume of 215,956. The firm has a market capitalization of $61.55 million, a PE ratio of -0.71 and a beta of 1.80. The stock has a 50 day simple moving average of $0.98 and a 200 day simple moving average of $0.97. Kronos Bio, Inc. has a 1-year low of $0.69 and a 1-year high of $1.60.
About Kronos Bio
(
Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Further Reading
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
